02Oct 2023
Targeting EB3–IP3R3 Interface with Cognate Peptide Protects from Acute Respiratory Distress Syndrome

Targeting EB3–IP3R3 Interface with Cognate Peptide Protects from Acute Respiratory Distress Syndrome

The study addresses Acute Respiratory Distress Syndrome (ARDS), proposing a novel pharmacological approach targeting the microtubule accessory factor EB3. Utilizing the CIPRI peptide to disrupt EB3–IP3R3 interaction, the treatment showed efficacy in mitigating calcium release, preserving endothelial junctions, and reducing inflammation-induced lung injury. This promising strategy presents potential for managing microvascular hyperpermeability.

  • #pulmonology

Like

Save

Share